MS
Margaret Sullivan
Age 58 • Bio Age 62
71
HealthSpan Score
+4y
Age Differential
Financial Position
Net Worth$8.5M
Liquid Assets$2.1M
Healthcare Reserve$850K
Intervention Budget$500K
Priority Alerts
Declining kidney function
Elevated inflammatory markers
Strong candidate for xenotransplant trials
Adequate financial reserves
Organ System Health
Heart
85
Score
56y
-2 vs actual
Kidneys
58
Score
67y
+9 vs actual
Liver
88
Score
55y
-3 vs actual
Cognitive
82
Score
57y
-1 vs actual
Lungs
74
Score
61y
+3 vs actual
Financial Runway vs Healthcare Costs
Stage 3 CKD (Declining) — United Therapeutics UKidney Xenotransplant
Show intervention scenario
Healthcare Reserve ($0.85M)
+ Intervention Budget ($1.35M total)
2026
UKidney Phase III Results
2029
FDA Approval Window
2031
Xenotransplant Window
Without Intervention
With UKidney Xenotransplant
Intervention Impact Analysis
Intervention Cost
$350K
UKidney Xenotransplant in 2031
Projected Savings
$915K
By 2040 vs status quo
Return on Investment
2.6x
Financial ROI by 2040
Dialysis Avoided
9+ years
Quality of life impact
Budget Status: Fully Funded
Total projected costs with intervention ($1.04M by 2040) remain within combined reserves of $1.35M
The Transformative Intervention Opportunity
United Therapeutics' UKidney xenotransplant (projected FDA approval 2029) represents a one-time investment of ~$350K that could eliminate the need for lifetime dialysis. For Margaret, this means avoiding 9+ years of dialysis treatments (3x weekly), preserving quality of life, and generating substantial long-term savings. Current reserves fully cover this intervention path.
Key Biomarkers
eGFR
mL/min
52
warningntProBNP
pg/mL
125
normalhba1c
%
5.8
normalapoB
mg/dL
95
normalHorizon Events Timeline
2025Annual comprehensive screening
$15K2026United Therapeutics UKidney Phase III results
2027Projected: Kidney function enters Stage 3b
2029Estimated UKidney FDA approval window
2031Potential xenotransplant window
$350K